ReviewJournal of clinical medicine2022
Secondary Osteoporosis and Metabolic Bone Diseases.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Unveiling the efficacy predictors and potential mechanisms ofFrontiers in immunology · 2026Pooled it
- Coumarins in musculoskeletal health: a systematic review.Frontiers in nutrition · 2026Pooled it
- Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.Aging clinical and experimental research · 2025Pooled it
- Meta-analysis of the effects of probiotic supplementation on bone turnover markers in middle-aged and elderly patients with osteoporosis.Frontiers in cellular and infection microbiology · 2025Pooled it
- Serum osteocalcin levels are inversely associated with UACR in Chinese DKD patients: a meta-analysis of 20 clinical studies.Frontiers in endocrinology · 2024Pooled it
- Pooled it
- Pediatric osteoporosis: a comprehensive imaging-based review of diagnosis, differential diagnosis, and etiology.Skeletal radiology · 2026Review
- Bone-specific alkaline phosphatase as a marker of bone formation: Clinical and imaging correlates.World journal of experimental medicine · 2026Review
- Cushing syndrome manifested during pregnancy and diagnosed following a fragility fracture of the pelvis.JCEM case reports · 2026Article
- Management of glucocorticoid-induced osteoporosis in rheumatic diseases.Best practice & research. Clinical rheumatology · 2026Review
- Combined Supplementation with Streptococcus Thermophilus Yilife-SST 01 and Bifidobacterium Bifidum BL-99 Mitigates Unloading-Induced Osteoporosis in Rats.Current microbiology · 2026Article
- Importance of Recognizing Renal Tubular Disorders as a Cause of Bone Hypomineralization and Fractures in Adults.Diagnostics (Basel, Switzerland) · 2026Review
- Midlife risk factors predict long-term hip fracture risk in women: a 35-yr follow-up.JBMR plus · 2026Article
- Article
- Bone health and chronic viral infections: A narrative literature review.World journal of virology · 2026Review
- Tailored Phytochitosomes as Targeted Nanotherapy for Alveolar Bone Regeneration in Diabetic Obese Rats.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Subclinically low BMD in young men is associated with compromised bone microarchitecture and lower lean mass.Journal of the Endocrine Society · 2026Article
- Mapping a Decade of Osteoporosis and Fracture Research: A Bibliometric Analysis (2015-2025).Journal of bone metabolism · 2026Article
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Effects of Rosmarinic Acid and Sinapic Acid on the Skeletal System in Ovariectomized Rats.Nutrients · 2026Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fragility fracture is a worldwide problem and a main cause of disability and impaired quality of life. It is primarily caused by osteoporosis, characterized by impaired bone quantity and or quality. Proper diagnosis of osteoporosis is essential for prevention of fragility fractures. Osteoporosis can be primary in postmenopausal women because of estrogen deficiency. Secondary forms of osteoporosis are not uncommon in both men and women. Most systemic illnesses and organ dysfunction can lead to osteoporosis. The kidney plays a crucial role in maintaining physiological bone homeostasis by controlling minerals, electrolytes, acid-base, vitamin D and parathyroid function. Chronic kidney disease with its uremic milieu disturbs this balance, leading to renal osteodystrophy. Diabetes mellitus represents the most common secondary cause of osteoporosis. Thyroid and parathyroid disorders can dysregulate the osteoblast/osteoclast functions. Gastrointestinal disorders, malnutrition and malabsorption can result in mineral and vitamin D deficiencies and bone loss. Patients with chronic liver disease have a higher risk of fracture due to hepatic osteodystrophy. Proinflammatory cytokines in infectious, autoimmune, and hematological disorders can stimulate osteoclastogenesis, leading to osteoporosis. Moreover, drug-induced osteoporosis is not uncommon. In this review, we focus on causes, pathogenesis, and management of secondary osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.